The Impact of an Antithrombotic Stewardship Program on Heparin-Induced Thrombocytopenia Management

J Pharm Pract. 2023 Dec;36(6):1343-1349. doi: 10.1177/08971900221116185. Epub 2022 Jul 18.

Abstract

Background: An antithrombotic stewardship program was implemented to reduce IV DTI use and increase fondaparinux and direct oral anticoagulant (DOAC) use for suspected or confirmed Heparin-induced thrombocytopenia (HIT). Objectives: This study evaluated the impact of an antithrombotic stewardship program on IV DTI utilization in patients with HIT. Methods: A retrospective analysis of adults receiving IV DTIs or fondaparinux from July 2016 to July 2017 (pre-stewardship) and October 2017 to July 2019 (post-stewardship) was conducted. Results: The median duration of IV DTI administration was not significantly different in HIT-negative patients between the pre- and post-stewardship cohorts (1.6 days (25th percentile (p25), 75th percentile (p75): .5, 3.3) vs 1.7 days (p25, p75: .9, 3.9), P = .31). The median duration of IV DTI administration in HIT-positive patients was 9.9 days (p25, p75: 7.6, 21.0) pre-stewardship and 7.3 days (p25, p75: 4.8, 16.5) post-stewardship (P = .18). For HIT-positive patients, the time from HIT diagnosis to discharge was 12.8 days (p25, p75: 8.9, 24.9) and 9.2 days (p25, p75: 4.0, 18.1) in the pre- and post-stewardship cohorts, respectively (P = .07). Fondaparinux and DOAC prescribing rates were 40.7% and 62.2% in the pre- and post-stewardship cohorts, respectively (P = .09). The percentage of patients with no contraindications to IV DTI alternatives receiving these agents increased from 31.2% to 78.6% (P = .01) following stewardship implementation. Conclusions: Intravenous DTI alternative utilization increased significantly after stewardship implementation. Stewardship implementation was associated with a non-statistically significant trend towards decreased IV DTI utilization and decreased length of stay for HIT-positive patients.

Keywords: antithrombotic stewardship; direct oral anticoagulant; direct thrombin inhibitors; fondaparinux; heparin induced thrombocytopenia.

MeSH terms

  • Adult
  • Anticoagulants / adverse effects
  • Fibrinolytic Agents
  • Fondaparinux / adverse effects
  • Heparin* / adverse effects
  • Humans
  • Retrospective Studies
  • Thrombocytopenia* / chemically induced

Substances

  • Heparin
  • Fondaparinux
  • Fibrinolytic Agents
  • Anticoagulants